Neurocrine Biosciences is reaffirmed as a Buy with a new fair value of $195.80, representing a 19% increase from the recent price. The upgrade is driven by the company's strong Q3 results, with key drugs INGREZZA and CRENESSITY outperforming expectations. The investment thesis highlights the undervalued early research engine, now assessed with industry-standard productivity, which significantly raises the company's fair value. However, risks remain for VYKAT XR due to safety and patent issues. The analyst would downgrade to Hold if the FDA restricts VYKAT XR or if CRENESSITY's market penetration stalls below 25%.
As of Nov 04, 2026 21:02 WIB, Neurocrine Biosciences (NBIX) trades at USD 167.49 on Pluang, showing a 1.60% gain in the last day. Despite the recent analyst upgrade and strong Q3 results, the platform data shows a high sell order activity at 91%, with typical investors holding for about 26 days. The market cap stands at $16.76 billion, highlighting the company's significant presence in the health sector.
